MRSN NASDAQ
Mersana Therapeutics, Inc.
1W: -0.2%
1M: +5.5%
3M: +264.4%
1Y: -22.9%
3Y: -80.0%
5Y: -95.8%
$29.08
Last traded 2025-12-31 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$40M
+9.9% ▲
5Y CAGR: -0.8%
Gross Profit
$40M
+134.9% ▲
5Y CAGR: -0.8%
Operating Income
-$73M
+57.1% ▲
Net Income
-$69M
+59.7% ▲
EPS (Diluted)
$-14.12
+61.8% ▲
EBITDA
-$63M
+61.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $828K | $43K | $27M | $37M | $40M |
| YoY Growth | -98.0% | -94.8% | +61716.3% | +38.7% | +9.9% |
| Cost of Revenue | $67M | $0 | $0 | $0 | $0 |
| Gross Profit | -$66M | $43K | $27M | $37M | $40M |
| Gross Margin | -7996.1% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D Expenses | $67M | $132M | $173M | $148M | $73M |
| SG&A Expenses | $22M | $37M | $57M | $60M | $41M |
| Operating Expenses | $89M | $169M | $230M | $208M | $114M |
| Operating Income | -$155M | -$169M | -$204M | -$171M | -$73M |
| Operating Margin | -18737.4% | -392693.0% | -766.6% | -463.9% | -181.1% |
| Interest Expense | $359K | $1M | $3M | $4M | $4M |
| Income Before Tax | -$88M | -$170M | -$204M | -$172M | -$69M |
| Tax Expense | $0 | $0 | $0 | $0 | $418K |
| Net Income | -$88M | -$170M | -$204M | -$172M | -$69M |
| Net Margin | -10633.5% | -395488.4% | -768.3% | -465.8% | -170.9% |
| EPS (Diluted) | $-35.80 | $-60.24 | $-54.51 | $-36.96 | $-14.12 |
| EBITDA | -$87M | -$168M | -$200M | -$166M | -$63M |
| Shares Outstanding | 2M | 3M | 4M | 5M | 5M |